2CUREX AB Despite what has surely been a challenging year for all of us, both as private persons as well as companies big and small, 2020 has been a landmark year for 2cureX.
With 2020 coming to an end, I believe we are all breathing a sigh of relief, this year has been a year that dramatically influenced our everyday life and confronted all of us what it means when a Pandemic becomes a reality. However, for our company, 2020 marks also the reward of years of preparation, it marks the official launch of the IndiTreat®. Something that fills me with pride and praise for all of those in 2cureX as well as several dedicated external partners that made this possible over the years. This marks a new chapter for 2cureX and as I'm writing this, we're in the process of identifying new colleagues to support our commercialization efforts.
During 2020 a lot of highlights led us to our launch phase.
Key achievements in 2020:
· Early Access Program to kick off transition period (https://www.biostock.se/2020/03/2curex-fran-fou-till-kommersialisering/)
· New commercial collaborations (https://www.2curex.com/2curex-is-accelerating-the-commercialization-of-inditreat-by-signing-two-distributor-agreements-to-prepare-for-launch-in-second-half-of-2020/)
· Public funding for expanded development (https://www.2curex.com/2curex-german-subsidiary-receives-a-grant-contribution-to-support-the-activities-towards-automation-of-the-inditreat-test/), A (https://www.2curex.com/2curex-germany-receives-an-additional-grant-for-adapting-inditreat-to-guide-immunotherapy-of-ovarian-cancer-patients/), B (https://www.2curex.com/2curex-german-subsidiary-receives-a-grant-contribution-to-support-the-activities-towards-automation-of-the-inditreat-test/), C (https://www.2curex.com/2curex-receives-third-payment-from-the-eu-horizon-2020-sme-instrument-program-2/), D (https://www.2curex.com/2curex-ab-establishes-collaboration-with-scandion-oncology-a-s-and-erasmus-medical-centre-rotterdam-in-drug-resistant-breast-cancer-patients/)
· Successful directed issue (https://www.2curex.com/2curex-completes-a-heavily-oversubscribed-directed-issue-of-approximately-sek-40-million/) and strengthened leadership (https://www.2curex.com/2curex-ab-expands-its-board-of-directors-with-michael-lutz-and-nils-brunner/)
· Last patient enrolled in our clinical trial in colorectal cancer (https://www.2curex.com/last-patient-successfully-enrolled-in-the-worlds-first-interventional-trial-with-3d-microtumors-as-guide-for-choice-of-cancer-treatment/)
· IndiTreat® launch at ESMO 2020 (https://www.2curex.com/2curex-launches-inditreat-biostock/)
· Commercial roadmap 2021 - 2023 (https://www.2curex.com/2curex-presents-commercial-roadmap-2021-2023/)
· New 2cureX website (https://www.2curex.com/2curex-launches-new-website/)
· www.IndiTreat.com available in Swedish (https://inditreat.com/sv/), Portuguese (https://inditreat.pt/), and Spanish (https://inditreat.pt/es/)
It is with great satisfaction to look back on our achievements in 2020, the 2cureX team did very well.
To continue the company's momentum, the 3-year focus has been outlined in a commercial roadmap for our operational activities, which includes expanding our sales and marketing team.
Key milestones for Q1 2021:
With our focus on 2021, I expect 2cureX to deliver on several important milestones that will fuel a new phase of 2cureX's development. As previously published to the market, we expect in the beginning of 2021 to deliver on:
· Clinical data from our colorectal cancer trial
· Strengthening of our commercial team and effort
With that I want to wish all our partners, shareholders and others that have supported 2cureX throughout 2020 a wonderful Christmas and a fabulous New Year.
Stay safe out there!
Best Wishes
Ole Thastrup, CEO 2cureX
https://news.cision.com/2curex/r/key-achievements-in-2020---an-inditreat---launch-year,c3261266
https://mb.cision.com/Public/16432/3261266/8f124ca75e724a2c.pdf
https://news.cision.com/2curex/i/2curex-xmas2020-logo-top,c2864319
(c) 2020 Cision. All rights reserved., source
